相似文献
1
Treatment of carrageenan induced arthritis by the platelet activating factor antagonist BN 50730.
Ann Rheum Dis. 1995 Feb;54(2):140-3. doi: 10.1136/ard.54.2.140.
2
Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis.
J Lipid Mediat Cell Signal. 1996 Jan;13(1):35-49. doi: 10.1016/0929-7855(95)00043-7.
3
Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.
J Pharmacol Exp Ther. 1990 Sep;254(3):976-81.
4
Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits.
Clin Exp Immunol. 1992 May;88(2):318-23. doi: 10.1111/j.1365-2249.1992.tb03080.x.
5
A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.
J Rheumatol. 1998 Aug;25(8):1502-7.
6
New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists.
Agents Actions. 1991 Jan;32(1-2):34-6. doi: 10.1007/BF01983304.
7
Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS.
Br J Pharmacol. 1994 Nov;113(3):994-1000. doi: 10.1111/j.1476-5381.1994.tb17091.x.
8
Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
J Lipid Mediat. 1991 Jan-Feb;3(1):13-26.
9
Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
Biochem Pharmacol. 1996 Jan 26;51(2):193-6. doi: 10.1016/0006-2952(95)02158-2.
10
Effect of BN 50727 on pathological findings and tissue platelet activating factor levels during ileal ischemia in newborn piglets.
J Pediatr Surg. 1996 Dec;31(12):1675-9. doi: 10.1016/s0022-3468(96)90046-9.
引用本文的文献
1
Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA2 in immortalized astrocytes (DITNC).
Neurochem Res. 2000 May;25(5):613-9. doi: 10.1023/a:1007550801444.
本文引用的文献
1
Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets.
Nature. 1981 Jan 22;289(5795):312-4. doi: 10.1038/289312a0.
2
Human neutrophil-derived platelet activating factor.
J Immunol. 1980 Feb;124(2):676-84.
3
Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: chemical ionization mass spectrometry of phospholipids.
Proc Natl Acad Sci U S A. 1980 Dec;77(12):7019-23. doi: 10.1073/pnas.77.12.7019.
4
5
Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor.
J Exp Med. 1972 Dec 1;136(6):1356-77. doi: 10.1084/jem.136.6.1356.
6
Antigenic release of paf-acether and beta-glucuronidase from alveolar macrophages of asthmatics.
Bull Eur Physiopathol Respir. 1987 Mar-Apr;23(2):119-24.
7
Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.
Biochem Biophys Res Commun. 1985 Oct 30;132(2):460-6. doi: 10.1016/0006-291x(85)91156-8.
8
Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
J Pharmacol Exp Ther. 1990 Dec;255(3):1320-7.
9
Presence of paf-acether in rheumatic diseases.
Ann Rheum Dis. 1992 Jan;51(1):29-31. doi: 10.1136/ard.51.1.29.
10
Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases.
Scand J Rheumatol. 1992;21(4):161-4. doi: 10.3109/03009749209099215.
Zotero 插件